- Patients evaluated or treated by multiple myeloma specialists at the National Cancer Institute Comprehensive Cancer Centers (NCICCC) experience improved survival vs those treated by community oncologists.
- Community oncologists with the highest patient volumes achieved comparable survival outcomes vs NCICCC specialists.
Why this matters
- Evidence suggests a link between improved survival in hematologic malignancies and treatment at high-volume facilities.
- Study to investigate associations between treatment facility characteristics and survival in 1029 patients with multiple myeloma.
- Data source: A North Carolina cancer registry.
- Funding: University Cancer Research Fund.
- Higher risk for mortality in patients:
- Not evaluated at an NCICCC facility: HR, 1.50; 95% CI, 1.21-1.86; P<.001.>
- Treated by a community provider vs an NCICCC multiple myeloma specialist, regardless of patient volume:
- High-volume community provider: HR, 1.29; 95% CI, 1.04-1.61; P<.05.>
- Low-volume community provider: HR, 1.47; 95% CI, 1.14-1.90; P<.01.>
- Retrospective data.